John Thompson
Directeur/Membre du Conseil chez NERVGEN PHARMA CORP.
Fortune : - $ au 31/05/2024
Profil
Mr. John C.
Thompson is an Independent Director at NervGen Pharma Corp.
and a Chief Executive Officer & Director at Cerevance, Inc. He is on the Board of Directors at NervGen Pharma Corp.
and Cerevance, Inc. Mr. Thompson was previously employed as a President & Chief Executive Officer by Neurana Pharmaceuticals, Inc., a President, Chief Executive Officer & Director by Anthera Pharmaceuticals, Inc., a Chief Operating Officer by Tetraphase Pharmaceuticals, Inc., a Chief Commercial Officer by Trius Therapeutics, Inc., and a Vice President-Marketing by Pfizer Inc. He received his undergraduate degree from McMaster University and an MBA from the University of Notre Dame.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NERVGEN PHARMA CORP.
-.--% | 23/05/2023 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de John Thompson
| Sociétés | Poste | Début |
|---|---|---|
| NERVGEN PHARMA CORP. | Directeur/Membre du Conseil | 13/04/2022 |
Cerevance, Inc.
 Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Directeur Général | - |
Anciens postes connus de John Thompson
| Sociétés | Poste | Fin |
|---|---|---|
| ANTHERA PHARMACEUTICALS, INC. | Directeur Général | 30/06/2018 |
| TETRAPHASE PHARMACEUTICALS, INC. | Directeur des opérations | 31/12/2015 |
| PFIZER, INC. | Sales & Marketing | 01/01/2010 |
Neurana Pharmaceuticals, Inc.
 Neurana Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neurana Pharmaceuticals, Inc. engages in a biotechnology industry. It focused on the development of drugs to treat neuromuscular disorders. The company was founded in 2013 and is headquartered in San Diego, CA. | Directeur Général | - |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Formation de John Thompson
| McMaster University | Undergraduate Degree |
| University of Notre Dame | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| ANTHERA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
Neurana Pharmaceuticals, Inc.
Neurana Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neurana Pharmaceuticals, Inc. engages in a biotechnology industry. It focused on the development of drugs to treat neuromuscular disorders. The company was founded in 2013 and is headquartered in San Diego, CA. | Health Technology |
| NervGen Pharma Corp. | |
Cerevance, Inc.
Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Health Technology |
